A recently formed biotech venture spun out of UC Berkeley, Axent Biosciences is structured around development of next generation stem cell therapies to address unmet medical needs in human health. The firm's platform technologies- in stem cell manufacturing and implantation - leverage more that two decades years of stem cell expertise and some 10 years of biomaterials engineering to overcome major bottlenecks in the clinical development pipeline efficiently to provide high quality stem cell therapeutics to large populations of patients in need. Specifically, the effort is to engineer biomaterial technology for two main bottlenecks in the development pipeline for stem cell therapy: manufacturing and implantation.
